U.S. market Closed. Opens in 17 hours 20 minutes

SABS | SAB Biotherapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue2.24M23.90M60.88M55.24M3.44M
Cost of Revenue3.75M3.29M1.65MN/AN/A
Gross Profit-1.51M20.61M59.22M55.24M3.44M
Operating Expenses36.57M28.92M13.39M34.68M12.12M
Selling, General & Admin20.05M16.38M17.09M6.77M4.10M
Research & Development16.52M36.44M57.18M27.91M8.02M
Other Operating ExpensesN/A-23.90M-60.88M4.00K2.59K
Operating Income-38.08M-28.92M-13.39M20.56M-8.67M
Other Expenses / Income-4.12M10.20M-3.75M-439.02K-312.75K
Before Tax Income-42.19M-18.72M-17.14M20.12M-8.99M
Income Tax Expenses-2.0025.63K299.95K473.15K431.07K
Net Income-42.19M-18.74M-17.44M20.12M-9.42M
Interest Expenses-315.28K301.58K294.46K469.15K428.48K
Basic Shares Outstanding5.52M4.35M2.73M2.54M43.47M
Diluted Shares Outstanding5.52M4.35M2.73M2.70M43.47M
EBITDA-34.33M-27.16M-11.71M21.14M-8.23M
EBITDA Margin-1,533.28%-113.62%-19.24%38.26%-239.25%
EBIT-42.51M-18.41M-16.85M21.06M-8.56M
EBIT Margin-1,898.58%-77.03%-27.68%38.13%-248.64%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙